|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 749.41 USD | -0.15% |
|
+0.40% | -2.91% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 26.25 | 11.42 | 8.49 | 7.31 | 5.91 | |||||
Return on Total Capital | 31.78 | 13.33 | 9.76 | 8.49 | 6.96 | |||||
Return On Equity % | 54.21 | 20.94 | 16.26 | 15.95 | 14.86 | |||||
Return on Common Equity | 54.21 | 20.94 | 16.26 | 15.95 | 14.86 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 66.74 | 57.67 | 52.32 | 49.99 | 44.57 | |||||
SG&A Margin | 11.35 | 17.38 | 20.06 | 20.8 | 18.82 | |||||
EBITDA Margin % | 57.45 | 43.83 | 35.48 | 32.59 | 29.6 | |||||
EBITA Margin % | 55.67 | 41.33 | 32.98 | 30.09 | 27.06 | |||||
EBIT Margin % | 55.67 | 41.03 | 32.27 | 29.19 | 25.81 | |||||
Income From Continuing Operations Margin % | 50.25 | 35.64 | 30.14 | 31.07 | 31.41 | |||||
Net Income Margin % | 50.25 | 35.64 | 30.14 | 31.07 | 31.41 | |||||
Net Avail. For Common Margin % | 50.25 | 35.64 | 30.14 | 31.07 | 31.41 | |||||
Normalized Net Income Margin | 34.76 | 26.46 | 22.03 | 21.2 | 23.38 | |||||
Levered Free Cash Flow Margin | 26.63 | 21.69 | 21.06 | 18.56 | 22.72 | |||||
Unlevered Free Cash Flow Margin | 26.85 | 22 | 21.41 | 18.8 | 22.91 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.75 | 0.45 | 0.42 | 0.4 | 0.37 | |||||
Fixed Assets Turnover | 4.79 | 3.36 | 3.26 | 3.14 | 2.82 | |||||
Receivables Turnover (Average Receivables) | 3.87 | 2.73 | 2.43 | 2.46 | 2.28 | |||||
Inventory Turnover (Average Inventory) | 2.76 | 2.37 | 2.51 | 2.51 | 2.53 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.56 | 5.06 | 5.69 | 4.73 | 4.13 | |||||
Quick Ratio | 2.98 | 4.16 | 4.82 | 3.86 | 3.28 | |||||
Operating Cash Flow to Current Liabilities | 1.8 | 1.6 | 1.34 | 1.12 | 1.14 | |||||
Days Sales Outstanding (Average Receivables) | 94.44 | 133.62 | 150 | 148.98 | 159.92 | |||||
Days Outstanding Inventory (Average Inventory) | 132.05 | 154.18 | 145.37 | 146.03 | 144.33 | |||||
Average Days Payable Outstanding | 35.26 | 37.56 | 33.92 | 33.58 | 39.12 | |||||
Cash Conversion Cycle (Average Days) | 191.23 | 250.23 | 261.45 | 261.44 | 265.14 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 14.38 | 11.92 | 10.74 | 10.01 | 9.51 | |||||
Total Debt / Total Capital | 12.58 | 10.65 | 9.7 | 9.1 | 8.68 | |||||
LT Debt/Equity | 10.55 | 11.92 | 10.67 | 9.91 | 9.39 | |||||
Long-Term Debt / Total Capital | 9.22 | 10.65 | 9.64 | 9.01 | 8.57 | |||||
Total Liabilities / Total Assets | 26.21 | 22.42 | 21.48 | 22.26 | 22.93 | |||||
EBIT / Interest Expense | 156.14 | 84.07 | 57.99 | 75.09 | 84.52 | |||||
EBITDA / Interest Expense | 161.13 | 89.82 | 64.02 | 84.5 | 97.75 | |||||
(EBITDA - Capex) / Interest Expense | 151.5 | 79.89 | 54.18 | 70.81 | 77.24 | |||||
Total Debt / EBITDA | 0.29 | 0.51 | 0.6 | 0.63 | 0.69 | |||||
Net Debt / EBITDA | -1.06 | -2.18 | -2.88 | -3.21 | -3.71 | |||||
Total Debt / (EBITDA - Capex) | 0.31 | 0.57 | 0.71 | 0.75 | 0.88 | |||||
Net Debt / (EBITDA - Capex) | -1.13 | -2.45 | -3.4 | -3.83 | -4.7 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 89.14 | -24.26 | 7.76 | 8.27 | 0.99 | |||||
Gross Profit, 1 Yr. Growth % | 131.06 | -34.84 | -2.25 | 3.46 | -9.97 | |||||
EBITDA, 1 Yr. Growth % | 142.18 | -42.51 | -12.77 | -0.56 | -8.26 | |||||
EBITA, 1 Yr. Growth % | 150.15 | -44.06 | -14.04 | -1.19 | -9.2 | |||||
EBIT, 1 Yr. Growth % | 150.15 | -44.48 | -15.23 | -2.08 | -10.69 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 129.86 | -46.28 | -8.87 | 11.61 | 2.09 | |||||
Net Income, 1 Yr. Growth % | 129.86 | -46.28 | -8.87 | 11.61 | 2.09 | |||||
Normalized Net Income, 1 Yr. Growth % | 149.34 | -42.66 | -10.29 | 4.18 | 11.39 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 135.81 | -46.89 | -9.03 | 10.27 | 8.19 | |||||
Accounts Receivable, 1 Yr. Growth % | 62.56 | -29.12 | 5.86 | 10.29 | -7.58 | |||||
Inventory, 1 Yr. Growth % | 1.81 | 23.09 | 7.44 | 19.64 | 3.68 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 8.09 | 8.06 | 10.18 | 14.03 | 11.4 | |||||
Total Assets, 1 Yr. Growth % | 48.19 | 14.86 | 13.23 | 14.14 | 7.41 | |||||
Tangible Book Value, 1 Yr. Growth % | 70.23 | 15.92 | 14.65 | 13.12 | 6.36 | |||||
Common Equity, 1 Yr. Growth % | 70.23 | 20.75 | 14.6 | 13.02 | 6.48 | |||||
Cash From Operations, 1 Yr. Growth % | 170.47 | -29.18 | -8.39 | -3.78 | 12.63 | |||||
Capital Expenditures, 1 Yr. Growth % | -10.2 | 6.92 | 21.78 | 5.19 | 18.85 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 276.49 | -38.72 | 5.12 | -4.59 | 23.62 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 268.12 | -38.37 | 5.37 | -4.91 | 23.04 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 56.55 | 19.69 | -9.66 | 8.01 | 4.57 | |||||
Gross Profit, 2 Yr. CAGR % | 79.14 | 21.82 | -20.19 | 0.56 | -3.49 | |||||
EBITDA, 2 Yr. CAGR % | 95.32 | 16.96 | -29.18 | -6.86 | -4.49 | |||||
EBITA, 2 Yr. CAGR % | 101.21 | 17.18 | -30.65 | -7.84 | -5.28 | |||||
EBIT, 2 Yr. CAGR % | 101.21 | 16.74 | -31.4 | -8.89 | -6.48 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 95.36 | 11.13 | -30.03 | 0.85 | 6.74 | |||||
Net Income, 2 Yr. CAGR % | 95.36 | 11.13 | -30.03 | 0.85 | 6.74 | |||||
Normalized Net Income, 2 Yr. CAGR % | 96.69 | 17.98 | -28.28 | -3.33 | 7.68 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 97.45 | 11.91 | -30.49 | 0.16 | 9.22 | |||||
Accounts Receivable, 2 Yr. CAGR % | 37.05 | 7.35 | 2.52 | 7.86 | 4.09 | |||||
Inventory, 2 Yr. CAGR % | 17.41 | 11.95 | 15 | 13.37 | 11.37 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 9.76 | 8.08 | 10.14 | 12.09 | 12.71 | |||||
Total Assets, 2 Yr. CAGR % | 31.07 | 30.47 | 14.04 | 13.69 | 10.73 | |||||
Tangible Book Value, 2 Yr. CAGR % | 30.09 | 40.45 | 15.28 | 13.88 | 9.69 | |||||
Common Equity, 2 Yr. CAGR % | 30.09 | 43.37 | 17.64 | 13.81 | 9.7 | |||||
Cash From Operations, 2 Yr. CAGR % | 70.71 | 38.4 | -19.46 | -6.11 | 4.1 | |||||
Capital Expenditures, 2 Yr. CAGR % | 13.34 | -2.01 | 14.11 | 13.18 | 11.81 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 73.35 | 48.86 | -19.93 | 0.15 | 8.6 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 72.94 | 47.71 | -19.61 | 0.09 | 8.17 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 46.18 | 22.9 | 15.57 | -4.04 | 5.62 | |||||
Gross Profit, 3 Yr. CAGR % | 48.74 | 28.06 | 13.2 | -12.98 | -3.08 | |||||
EBITDA, 3 Yr. CAGR % | 50.98 | 30.15 | 6.07 | -20.7 | -7.33 | |||||
EBITA, 3 Yr. CAGR % | 52.26 | 31.56 | 5.68 | -21.97 | -8.29 | |||||
EBIT, 3 Yr. CAGR % | 52.26 | 31.23 | 4.93 | -22.76 | -9.5 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 48.93 | 27.04 | 4.02 | -18.25 | 1.26 | |||||
Net Income, 3 Yr. CAGR % | 48.93 | 27.04 | 4.02 | -18.25 | 1.26 | |||||
Normalized Net Income, 3 Yr. CAGR % | 51.02 | 30.65 | 7.68 | -18.77 | 1.35 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 50.08 | 27.45 | 4.44 | -18.94 | 2.77 | |||||
Accounts Receivable, 3 Yr. CAGR % | 30.58 | 10.01 | 19.55 | 4.93 | 4.55 | |||||
Inventory, 3 Yr. CAGR % | 19.23 | 19.27 | 10.42 | 16.52 | 10.04 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 10.57 | 9.19 | 9.45 | 11.42 | 11.86 | |||||
Total Assets, 3 Yr. CAGR % | 29.42 | 25.43 | 24.45 | 14.08 | 11.56 | |||||
Tangible Book Value, 3 Yr. CAGR % | 28.93 | 25.17 | 31.26 | 14.56 | 11.32 | |||||
Common Equity, 3 Yr. CAGR % | 28.93 | 26.9 | 33.06 | 16.08 | 11.31 | |||||
Cash From Operations, 3 Yr. CAGR % | 47.76 | 27.32 | 20.62 | -14.54 | -0.24 | |||||
Capital Expenditures, 3 Yr. CAGR % | 12.94 | 11.16 | 5.35 | 11.05 | 15.04 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 46.75 | 22.86 | 32.35 | -15.11 | 7.43 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 46.53 | 22.89 | 31.78 | -14.98 | 7.22 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 27.02 | 15.7 | 20.58 | 16.71 | 11.04 | |||||
Gross Profit, 5 Yr. CAGR % | 33.72 | 15.6 | 16.06 | 16.26 | 6.21 | |||||
EBITDA, 5 Yr. CAGR % | 45.1 | 19.11 | 11.65 | 13.84 | 1.71 | |||||
EBITA, 5 Yr. CAGR % | 46.39 | 19.33 | 11.28 | 14.1 | 1.15 | |||||
EBIT, 5 Yr. CAGR % | 46.39 | 19.15 | 10.8 | 13.41 | 0.2 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 55.25 | 29.34 | 10.09 | 15.84 | 5.1 | |||||
Net Income, 5 Yr. CAGR % | 55.25 | 29.34 | 10.09 | 15.84 | 5.1 | |||||
Normalized Net Income, 5 Yr. CAGR % | 46.17 | 19.92 | 12.24 | 15.82 | 7.7 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 56.35 | 29.88 | 10.31 | 15.74 | 6.33 | |||||
Accounts Receivable, 5 Yr. CAGR % | 25.71 | 11.88 | 18.54 | 16.76 | 13.03 | |||||
Inventory, 5 Yr. CAGR % | 37.34 | 27.03 | 17.52 | 16.88 | 10.8 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 10.82 | 9.79 | 10.4 | 10.76 | 10.74 | |||||
Total Assets, 5 Yr. CAGR % | 29.54 | 27.23 | 23.03 | 20.59 | 18.77 | |||||
Tangible Book Value, 5 Yr. CAGR % | 33.36 | 28.76 | 23.28 | 20.53 | 22.16 | |||||
Common Equity, 5 Yr. CAGR % | 33.36 | 29.83 | 24.29 | 21.49 | 23.17 | |||||
Cash From Operations, 5 Yr. CAGR % | 36.65 | 30.86 | 15.92 | 12.71 | 13.72 | |||||
Capital Expenditures, 5 Yr. CAGR % | 1.52 | 16.7 | 13.41 | 11.96 | 7.89 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 33.17 | 23.91 | 15.33 | 13.11 | 22.28 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 33.28 | 23.83 | 15.41 | 13.1 | 21.77 |
- Stock Market
- Equities
- REGN Stock
- Financials Regeneron Pharmaceuticals, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















